Dimerix Ltd has released a press release.
FDA confirms Proteinuria as Primary Endpoint for US approval
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Dimerix
- S&P DJI Announces March 2025 Quarterly Rebalance
- Dimerix receives initial upfront payment from FUSO
- Half-Year Financial Report & Appendix 4D - 31 December 2024
- First Paediatric Patient Recruited for ACTION3
- Dimerix enters Development and License Agreement for Japan
Later from Dimerix
- Trading Halt
- Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
- Dimerix Licenses DMX-200 in the US
- Investor Webinar and Presentation
- Dimerix receives initial upfront payment from Amicus
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix